NCT00872716

Quetiapine in Specific Phobia

Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: University Hospital Muenster · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study hypothesis is that quetiapine XR has anxiolytic properties. The study aims to investigate the putative anxiolytic properties of quetiapine XR in patients with anxiety disorders. Therefore, in a proof-of-concept design patients with simple phobia will be selected to investigate specific anxiolytic and antipanic activity during acute anxiety. Moreover, in a combined fMRI/visual stimulus presentation paradigm activity of fear-network associated brain structures such as the amygdala will be investigated under treatment with quetiapine XR or placebo. Additionally, genetic factors potentially mediating anxiolytic properties of quetiapine will be studied.

Conditions

• Specific Phobia

Interventions

Type	Name	Description
DRUG	Quetiapine XR	100 mg single-dose Quetiapine XR
OTHER	Placebo	Placebo

Timeline

• Start date: 2009-04-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2009-03-31
• Last updated: 2011-03-31

Locations

1 site across 1 country: Germany